Clinical Trial Update: Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A combined Phase 1/2 trial evaluating lenalidomide after chemotherapy and stem cell transplant in various forms of recurrent or resistant non-Hodgkin lymphoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Anaplastic Large Cell Lymphoma Alk-negative
• Mantle Cell Lymphoma
• Mature T- and Nk-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Transformed Non-hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: University of Nebraska | Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-11-08